Phase 2 Cervical Cancer Trial, Recruiting NCT07169734 Sponsor: Alentis Therapeutics AG Condition: Cervical Cancer
Back to Cervical Cancer

Phase 2 Cervical Cancer Trial, Recruiting

NCT07169734
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been confirmed through lab testing (tissue/cell samples) to have one of these cancers that has spread: colorectal cancer, bile duct cancer (intrahepatic cholangiocarcinoma), squamous non-small cell lung cancer, bladder/urinary tract cancer (urothelial carcinoma), or cervical squamous cell cancer
  • Scans or imaging have shown that your cancer has continued to grow or spread since your last treatment
  • You have provided a tissue sample to be tested for a specific protein called Claudin-1 (CLDN1) at a central lab
  • For the early dose-finding part of the trial: you have already tried the standard available treatments for your cancer and either they stopped working or you could not tolerate them
  • For the later parts of the trial: you have tried 1 to 2 standard treatments that either stopped working or you could not tolerate them — and if your cancer has a specific targetable mutation, you have also tried the relevant targeted therapy
  • Your cancer can be measured on scans according to standard criteria (called RECIST 1.1)
  • You are in good enough general health to carry out everyday activities with no or minimal limitations (confirmed with trial site)
  • Your blood tests show your bone marrow, liver, kidneys, and other organs are working well enough as required by the trial

Who may not be able to join:

  • For lung or cervical cancer patients: your cancer is mainly a non-squamous type or is a type called adenocarcinoma
  • You have received other cancer treatments too recently before starting this trial (confirm with trial site for exact timeframes)
  • Your cancer is growing or spreading very rapidly
  • You have active cancer that has spread to your brain or spinal fluid
  • You have a history of, or currently have, lung inflammation (not caused by infection) that has needed steroid treatment, or you currently have significant lung inflammation requiring steroids or immune-suppressing medicines
  • You have serious or significant bleeding in your digestive system (stomach or intestines)
  • You currently have an active infection that requires treatment with medicines given throughout your body (such as IV or oral antibiotics)
  • You have any other medical condition, past treatment, or abnormal test result that could interfere with the trial results (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 2 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Alentis Therapeutics AG
Registry
ClinicalTrials.gov
Start date
26 August 2025
Est. completion
5 April 2029

Where this trial is recruiting

🇫🇷 France Hong Kong 🇮🇹 Italy 🇳🇱 Netherlands 🇸🇬 Singapore 🇪🇸 Spain 🇺🇸 United States

Primary endpoints

Number of Patients with Dose Limiting Toxicities (DLTs) (Phase I); Number of Patients with Adverse Events (Phase I); Overall Response Rate (ORR) (Phase I); Duration of Response (DoR) (Phase I); Overall Response Rate (ORR) (Phase II); Duration of Response (DoR) (Phase II)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 2 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov